A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors
出版年份 2014 全文链接
标题
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors
作者
关键词
ABT-263, Carboplatin, Paclitaxel, Phase I
出版物
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 5, Pages 976-984
出版商
Springer Nature
发表日期
2014-06-05
DOI
10.1007/s10637-014-0116-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- From sentencing to execution – the processes of apoptosis
- (2015) Kelly L. Moffitt et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
- (2012) M. Wong et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Paclitaxel, Ifosfamide and Cisplatin (TIP) Beyond Its Original Indication for Salvage Treatment of Germ Cell Tumors
- (2011) Martin H. Voss et al. Oncology Research and Treatment
- Mitochondrial signaling in cell death via the Bcl-2 family
- (2010) Brian Leibowitz et al. CANCER BIOLOGY & THERAPY
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The status of platinum anticancer drugs in the clinic and in clinical trials
- (2010) Nial J. Wheate et al. DALTON TRANSACTIONS
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis
- (2010) Sakuma ONCOLOGY REPORTS
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
- (2009) M. H. Kang et al. CLINICAL CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Tumor resistance to apoptosis
- (2008) Simone Fulda INTERNATIONAL JOURNAL OF CANCER
- Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy
- (2008) Asfar S. Azmi et al. JOURNAL OF CELLULAR PHYSIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started